Filana Therapeutics, Inc.
FLNAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Filana Therapeutics, Inc. focuses on Biotechnology services and products. Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. The $34.0M market capitalization puts FLNA squarely in micro-cap range for its industry. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Market Cap
$34.0M
Beta
-0.66
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.87
EPS (Fwd)
—
ROE
-55.8%
ROA
-7.1%
Cash
$82.7M
Total Debt
$0
Free CF
$4.0M
52W Change
-84.1%
Annual Financials
Cash vs Debt
Where FLNA stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, FLNA finished 40.16% below its 150-day moving average ($1.22) and 49.31% below its 200-day moving average ($1.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FLNA overbought or oversold?
At the October 15, 2026 close, FLNA's RSI(14) was 46.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Filana Therapeutics, Inc. reports $82.7M in cash and $0 in total debt. The company generates $4.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -55.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
FLNA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. No single metric tells the full story. Reviewing FLNA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.